European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery · 2026
Concomitant Tricuspid Valve Surgery During HeartMate 3 LVAD Implantation and Long-Term Outcomes: Insights From the ELEVATE Registry.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Färber Gloria, Zimpfer Daniel, Garbade Jens, Lavee Jacob, Morshuis Michiel, Shaw Steven, Gustafsson Finn, Gazzola Carlo, Wang AiJia, Saeed Diyar, ELEVATE Investigators
Аннотация
OBJECTIVES: To assess whether tricuspid valve surgery (TVS) during HeartMate 3 (HM3) left ventricular assist device (LVAD) implantation affects long-term survival and outcomes.
METHODS: The ELEVATE registry enrolled 540 HM3 patients across 26 centres; 463 undergoing primary LVAD implantation and at least mild tricuspid regurgitation (TR) formed this analysis. Concomitant TVS was performed in 70 (15.1%) patients. Five-year outcomes (survival, functional capacity, end-organ function, adverse events) were compared with those with similar severity of TR not receiving TVS in both overall population (with TVS n = 70 vs without TVS n = 264) and matched groups (each group n = 67, primary analysis cohort).
RESULTS: In the matched cohort, baseline demographics of patients with or without TVS showed no differences in age (57.9 ± 10.8 vs 57.3 ± 10.0; P = .728), sex (male, 92.5% vs 94.0%; P = 1.000), preoperative short-term mechanical circulatory support rate (6.0% vs 9.0% P = .744), New York Heart Association (NYHA) class and quality of life (QoL) score, and end-organ function. Preoperatively, patients with TVS had shorter 6-minute walk distances (6MWD; 58.0 ± 109.0 m vs 105.3 ± 154.0 m; P = .081). At 5 years, patients with TVS showed no differences in survival (69.0% vs 59.3%, P = .67), 6MWD (311.1 ± 129.5 m vs 295.6 ± 137.7 m, P = .758), QoL score, or end-organ function while presented a lower risk of right heart failure (EPPY 0.038 vs 0.092, P = .03).
CONCLUSIONS: In the ELEVATE registry, concomitant TVS during HM3 implantation was not associated with differences in 5-year survival; however, it may have a positive effect on functional capacity and right heart function.
CLINICAL REGISTRATION NUMBER: NCT02497950.
METHODS: The ELEVATE registry enrolled 540 HM3 patients across 26 centres; 463 undergoing primary LVAD implantation and at least mild tricuspid regurgitation (TR) formed this analysis. Concomitant TVS was performed in 70 (15.1%) patients. Five-year outcomes (survival, functional capacity, end-organ function, adverse events) were compared with those with similar severity of TR not receiving TVS in both overall population (with TVS n = 70 vs without TVS n = 264) and matched groups (each group n = 67, primary analysis cohort).
RESULTS: In the matched cohort, baseline demographics of patients with or without TVS showed no differences in age (57.9 ± 10.8 vs 57.3 ± 10.0; P = .728), sex (male, 92.5% vs 94.0%; P = 1.000), preoperative short-term mechanical circulatory support rate (6.0% vs 9.0% P = .744), New York Heart Association (NYHA) class and quality of life (QoL) score, and end-organ function. Preoperatively, patients with TVS had shorter 6-minute walk distances (6MWD; 58.0 ± 109.0 m vs 105.3 ± 154.0 m; P = .081). At 5 years, patients with TVS showed no differences in survival (69.0% vs 59.3%, P = .67), 6MWD (311.1 ± 129.5 m vs 295.6 ± 137.7 m, P = .758), QoL score, or end-organ function while presented a lower risk of right heart failure (EPPY 0.038 vs 0.092, P = .03).
CONCLUSIONS: In the ELEVATE registry, concomitant TVS during HM3 implantation was not associated with differences in 5-year survival; however, it may have a positive effect on functional capacity and right heart function.
CLINICAL REGISTRATION NUMBER: NCT02497950.